EMAIL THIS PAGE TO A FRIEND

Medical oncology (Northwood, London, England)

Prognosis significance of HER2 status and TACC1 expression in patients with gastric carcinoma.


PMID 25297519

Abstract

HER2 amplification and/or expression occurs in gastric carcinoma (GC), but the role of HER2 in the prognosis of GC remains unclear. The dysregulation of transforming acidic coiled coil 1 (TACC1), a downstream gene of HER2, is thought to be involved in the development of GC. The aim of this study was to investigate the role and relationship of HER2 and TACC1 in GC. The expression of HER2 and TACC1 was analyzed using immunohistochemistry on 129 primary resected GC patients, and HER2 amplification was additionally determined by FISH. The data on clinicopathological features and relevant prognostic factors in these patients were analyzed. The expression (3+, 2+ and 1+) and the amplification of HER2 was observed in 57 cases (44.2 %) and 25 cases (19.4 %), respectively, and the correlation between HER2 expression and amplification was strong (p < 0.001). According to the FDA criteria, 24 cases (18.6 %) would have been considered as HER2 positive. A total 62 (48.1 %) GC tissues showed positive cytoplasmic staining of TACC1. There was a significant and positive association between TACC1 and HER2. HER2 positive was significantly associated with TNM stage (p = 0.019), and TACC1 expression was significantly associated with lymph node metastasis (p = 0.004) and TNM stage (p = 0.004). TNM stage, TACC1 expression and co-positive of both HER2 and TACC1 were independent prognostic factors. TACC1 expression is an independent prognostic indicator of GC. The correlation between TACC1 expression and HER2-positive status indicated a possible synergistic regulation of the two molecules and co-positive of both HER2 and TACC1 maybe a more valuable prognostic marker.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

SAB4300350
Anti-ERBB2 (Ab-1221/1222) antibody produced in rabbit, affinity isolated antibody
SAB4300351
Anti-ERBB2 (Ab-1248) antibody produced in rabbit, affinity isolated antibody
SAB4300349
Anti-ERBB2 (Ab-877) antibody produced in rabbit, affinity isolated antibody
GW22631 Anti-ERBB2 antibody produced in chicken, affinity isolated antibody, buffered aqueous solution
HPA001383
Anti-HER2 antibody produced in rabbit, Ab1, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB4500782
Anti-HER2 antibody produced in rabbit, affinity isolated antibody
SAB4500783
Anti-HER2 antibody produced in rabbit, affinity isolated antibody
SAB4500787
Anti-HER2 antibody produced in rabbit, affinity isolated antibody
SAB4500789
Anti-HER2 antibody produced in rabbit, affinity isolated antibody
HPA024702
Anti-TACC1 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
E2777 Monoclonal Anti-c-erbB-2 antibody produced in mouse, ~2 mg/mL, clone HER2-96, purified immunoglobulin, buffered aqueous solution
WH0002064M6
Monoclonal Anti-ERBB2 antibody produced in mouse, clone 4B8, purified immunoglobulin, buffered aqueous solution
SAB1403787
Monoclonal Anti-ERBB2 antibody produced in mouse, clone 3B1, purified immunoglobulin, buffered aqueous solution
AMAB90628
Monoclonal Anti-HER2 antibody produced in mouse, Prestige Antibodies® Powered by Atlas Antibodies, clone CL0269, purified immunoglobulin, buffered aqueous glycerol solution
AMAB90627
Monoclonal Anti-HER2 antibody produced in mouse, Prestige Antibodies® Powered by Atlas Antibodies, clone CL0268, purified immunoglobulin, buffered aqueous glycerol solution